BioArctic awarded patent by EPO for potential Alzheimer's antibodies

By The Science Advisory Board staff writers

January 27, 2021 -- The European Patent Office (EPO) has granted Swedish-based biopharmaceutical company BioArctic patent EP 2, 558, 968 B1 for its novel antibodies that could be developed to treat Alzheimer's disease.

The antibodies target a truncated form of amyloid beta (pE3-Aβ) and are part of BioArctic's AD1503 program. Monomers of pE3-Aβ are highly prone to aggregate, leading to the formation of harmful amyloid beta aggregates, which cause the symptoms associated with Alzheimer's disease. The company believes that focusing on other forms of amyloid beta species in the Alzheimer's disease cascade can open the door for future treatment possibilities.

Precision BioSciences nabs patent for CAR construct tech
Precision BioSciences has received a notice of allowance from the U.S. Patent and Trademark Office for patent application, No. 16/908, 030. The patent...
Tonix files patent for proprietary monoclonal antibody
Tonix Pharmaceuticals has filed a patent application for TNX-1500, a humanized monoclonal antibody directed against the CD40-ligand, with the World Intellectual...
Lantern Pharma, Califia Pharma to launch ADC program
Lantern Pharma is launching the development of an antibody-drug conjugate (ADC) program through an evaluation and potential development agreement with...
Prevail Therapeutics granted gene therapy patent
The U.S. Patent and Trademark Office has issued a composition of matter patent (No. 10,837,028) to Prevail Therapeutics for its adeno-associated viral...
Pressure BioSciences awarded U.S. patent for Ultra Shear Technology
Pressure BioSciences has been awarded U.S. patent No. 10,823,259 for its Ultra Shear Technology platform, bringing the company's intellectual property...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter